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Ligand-regulatable erythropoietin production by plasmid injec- Erythropoietin (Epo) is a 30-kD glycoprotein synthe-
tion and in vivo electroporation. sized in adult renal cells and functions as the major regu-
Background. The development of an in vivo gene transfer lator of mammalian erythropoiesis [1]. Serum humanapproach to deliver physiologic levels of recombinant proteins
erythropoietin (hEpo) levels are controlled transcrip-to the systemic circulation would represent a significant ad-
tionally in response to tissue hypoxia or anemia [2]. Thevance in the treatment of protein deficiency disorders. How-
ever, the ability to regulate transgene expression is of para- secreted protein increases erythrocyte production by
mount importance for safe and effective gene transfer therapy. stimulating the proliferation and preventing the apopto-
Methods. We developed two plasmids, one encoder of chi- sis of erythroid precursors. Most patients with end-stagemeric GeneSwitch protein, and the other an inducible trans-
renal disease (ESRD) who are treated with hemodialysisgene for human erythropoietin (Epo). The level of secretion
suffer from severe anemia resulting from inappropriatelyof Epo into the serum was modulated by intraperitoneal admin-
istration of mifepristone (MFP). Rats were divided into four low levels of serum hEpo [3]. These patients are currently
groups: one group administered Epo plasmid with MFP for 50 treated with repeated intravenous or subcutaneous infu-
days, a second group administered Epo plasmid with MFP for
sion of recombinant hEpo [3]. The Epo-responsive ane-15 days and then again from day 30 to day 50, a third group
mia represents an excellent model for studies designedadministered Epo plasmid without MFP, and a fourth group
administered control plasmid. A pair of electrodes was inserted to develop an in vivo gene transfer approach for the
into the muscle of the right thigh, 100 mg of each plasmid was treatment of serum protein deficiencies.
injected, and in vivo electroporation (8 pulses at 100 V for 50 The permanent and regulated systemic delivery of ther-
msec) was performed.
apeutic proteins from engineered tissue appears to beResults. The presence of vector-derived Epo mRNA was de-
one of the most attractive goals of gene therapy. Differ-tected by RT-PCR only in the Epo plasmid and MFP() groups.
The hematocrit levels increased continuously, from the pre-injec- ent strategies can be considered for installing a source
tion level of 41.2% to 55.0% on day 30 and 53.8% on day 50 in of recombinant protein in a mammalian organism. Intra-
the Epo plasmid and MFP() groups. In the MFP re-challenged muscular adenovirus injection has been reported to ef-group, the hematocrit levels rose up to day 15, fell after 20 to
fectively induce Epo in rats. [4–7]. The autologous cells30 days, and then rose again after MFP re-administration. The
previously engineered in vitro by retrovirus-mediatedserum Epo levels increased only in the Epo plasmid and MFP()
groups. There were no significant changes in hematocrit levels gene transfer can be engrafted into syngeneic recipients.
and Epo levels in the Epo plasmid and MFP() group. This technique has been used to achieve prolonged Epo
Conclusion. Epo gene transfer with the GeneSwitch system delivery in mice [8–10]. Several novel methods recentlyby in vivo electroporation is a useful procedure for efficient
have been used to regulate the expression of therapeuticdrug-regulated delivery of Epo.
hormones such as growth hormone and Epo over long
periods. In subjects treated by an intramuscular injection
of adeno-associated vector, doxycycline was found to ade-
quately control Epo production [11]. Stable long-term
delivery of Epo and growth hormone was developed
under pharmacological control of rapamycin using twoKey words: gene therapy, plasmid, mifepristone, renal failure, electro-
poration, protein deficiency disorders, glycoprotein, GeneSwitch system. adeno-associated virus vectors [12, 13]. Several reports
demonstrated that adenovirus vector induced an efficientReceived for publication September 18, 2001
expression of Epo in immunodeficient mice [14]. How-and in revised form June 29, 2002
Accepted for publication July 3, 2002 ever, the immunoresponse to adenovirus prevents long
and stable gene expression in immunocompetent mice [13]. 2002 by the International Society of Nephrology
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Recently, an improved helper-dependent adenoviral vec- In vitro transfection and hEpo assay in LLC-PK1 cells
tor allowed persistent gene expression after intramuscular LLC-PK1 cells originally purchased from the Ameri-
delivery [15]. Naked DNA of Epo injection and muscle can Type Culture Collection (Rockville, MD, USA)
electroporation have been reported to cause efficient Epo were grown in Dulbecco’s modified Eagle’s medium
production and elevation of hematocrit [16]. However, (DMEM; Gibco BRL, Grand Island, NY, USA) supple-
regulation of Epo production is not well controlled by mented with 50 IU/mL penicillin, 50 g/mL streptomy-
adenovirus-mediated gene transfer or plasmid injection cin, and 10% heat-inactivated fetal calf serum (FCS;
with in vivo electroporation. The ability to regulate trans- Gibco). Cells were cultured at 37C in 5% CO2. LLC-gene expression will become paramount for the safety and PK1 cells were transfected with plasmid DNAs [15 g
efficacy of gene transfer therapy. The GeneSwitch system of pGene/V5-hEpo or pGene/V5 (control) plus 15 g of
for ligand-dependent transgene regulation is based on
pSwitch] by the electroporation method as previouslythe unusual properties of a C-terminal truncation of the
described [18]. After 24 hours to 14 days, cell cultureligand-binding domain (LBD) of the human progester-
supernatants were assayed for secreted hEpo using ra-one receptor [17]. A ligand-dependent, site-specific tran-
dioimmunoassay (RIA; Amersham Pharmacia Biotech,scription factor is generated by linking the modified LBD
Buckinghamshire, UK).to a heterologous DNA-binding domain (GAL4) and a
human transcription activation domain [nuclear factor-B Intramuscular plasmid injection and electroporation
(NF-B) p65]. The chimeric protein is activated by anti-
Male Sprague-Dawley rats weighing 100 to 150 g wereprogesterone to form a homodimer, which binds to the
anesthetized with pentobarbiturate sodium. The medialpromoter of a target gene with GAL4 consensus sequence
side of the right thigh was used for in vivo electropora-and activates its transcription. In this report we describe
tion. A 1-cm incision was made in the skin and the musclethe construction of an efficient and ligand-regulatable
was exposed. Plasmid DNAs (100 g of pGene/V5-hEpoEpo production system using this GeneSwitch system
and 100 g of pSwitch) were injected intramuscularlywith naked plasmid and in vivo electroporation.
with a 27-gauge needle into the central portion of the two
needle electrodes, and electric pulses were immediately
METHODS delivered to the muscle. Because electroporation with
GeneSwitch system plasmid construction eight electric pulses of 100 V at 50 msec apart has been
We constructed a mifepristone (MFP)-inducible hEpo reported to induce efficient gene transfer [16], this proto-
expression system, the GeneSwitch system, according to col was used here. The electric pulse was delivered by an
the manufacturer’s protocol (Invitrogen, Carlsbad, CA, electric pulse generator (Electro Square Porator T820;
USA). An inducible expression plasmid, pGene/V5, was BTX, San Diego, CA, USA) and monitored by a graphic
under the control of a hybrid promoter containing GAL4 analyzer (MVC540r; BTX). The electrodes consisted of
upstream activating sequences (UAS) and the adenovirus a pair of stainless steel needles measuring 8 mm in length
E1b TATA box. We inserted a full-length BamH1-Not1 and 0.4 mm in diameter, with a fixed distance of 4 mm
fragment of the coding region of hEpo into this inducible between them. Blood samples (200 L) were collected
expression plasmid (pGene/V5-hEpo). A regulatory plas- at the indicated days.
mid, pSwitch, which encodes a fusion protein consisting
of the yeast GAL4 DNA binding domain (DBD), a trun- Western blot analysis
cated human progesterone receptor ligand binding do- Cells and muscle tissues were lysed in sodium dodecyl
main (hPR-LBD), and the human p65 activation domain sulfate (SDS) sample buffer [50 mmol/L Hepes, pH 7.5,
(AD) from NF-B, was used for in vivo electroporation
150 mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L egtazic(Fig. 1).
acid (EGTA), 10% glycerol, 1% Triton X-100, 1 g/mLThe GeneSwitch system contains a hybrid regulatory
aprotinin, 1 g/mL leupeptin, 1 mmol/L phenylmethyl-protein containing a DBD from the yeast GAL4 protein,
sulfonyl fluoride (PMSF), 0.1 mmol/L sodium orthovana-a truncated LBD from the human progesterone receptor,
date] at 4C. After incubation for five minutes, lysatesand AD from the human NF-B protein. This hybrid
were centrifuged at 4C for 15 minutes at 10,000  g.regulatory protein binds to the synthetic steroid, MFP,
The soluble lysates were mixed at a 1:4 ratio with 5and functions as a ligand-dependent transcription factor
Laemmli buffer, heated for five minutes at 95C, loadedto induce the expression of hEpo. As shown in Figure 1,
into lanes (30 g per lane) and separated by SDS-poly-in the presence of MFP, the GeneSwitch protein, GAL4-
acrylamide gel electrophoresis (SDS-PAGE) using 5 andDBD-hPR-LBD, binds to MFP and acts as a transcrip-
20% acrylamide for stacking and resolving gels, respec-tion factor for the pGene/V5-hEpo. In the absence of
tively. Protein was transferred to nitrocellulose (poreMFP, GAL4-DBD-hPR-LBD does not bind to the GAL4
size 0.45 m; Schleicher and Schuell, Keene, NH, USA)UAS site of pGene/V5-hEpo plasmids, and does not
stimulate the transcription of hEpo. and probed with polyclonal antibodies against hEpo
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Fig. 1. Schema of the GeneSwitch system. An inducible expression plasmid, pGene/V5, under the control of a promoter containing GAL4 upstream
activating sequences (UAS) and the adenovirus E1b TATA box. The full length of the coding region of human erythropoietin (hEpo) was inserted
(pGene/V5-hEpo). A regulatory plasmid, pSwitch, which encodes a fusion protein consisting of the yeast GAL4 DNA binding domain (DBD), a
truncated human progesterone receptor ligand binding domain (hPR-LBD), and the human p65 activation domain (AD) from nuclear factor-B
(NF-B) was used for in vivo electroporation. The hybrid regulatory protein containing a DBD from the yeast GAL4 protein, a truncated ligand-
binding domain (LBD) from the human progesterone receptor, and AD from the human NF-B protein is expressed. This hybrid regulatory
protein binds to the synthetic steroid, mifepristone, and functions as a ligand-dependent transcription factor to induce the expression of hEpo.
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The chain reaction (PCR) was performed using the GeneAmp
DNA Amplification Reagent Kit (Perkin-Elmer Cetus,anti-human Epo antibody (Santa Cruz Biotechnology),
diluted 1/1000, were detected using horseradish peroxi- Norwalk, CT, USA), with pGene/V5-hEpo, pSwitch, and
hEpo cDNA specific primers prepared on a DNA synthe-dase (HRP)-conjugated rabbit anti-mouse IgG and visu-
alized by the Amersham enhanced chemiluminescence sizer (Applied Biosystems Inc., Tokyo, Japan). The sequence
(ECL) system (Amersham Corp., Arlington Heights, IL, of pGene/V5-hEpo primer 1 (antisense) was 5-TCGA
USA) after extensive washing of the membranes. CCCGCGTAAGAGCTCGG-3, and that of primer 2
(sense) 5-GCTAGCAGTAATACTAACGG-3. The
Detection of anti-hEpo antibody in rat serum predominant cDNA amplification product was predicted
Anti-human erythropoietin antibody was detected to be 426 bp in length (the distance between primers plus
from rat serum by absorbance experiments as described the primer length). The sequence of pSwitch primer 1
previously [19]. Briefly, LLC-PK1 cell lysate containing (antisense) was 5-GAATGATCTCCCGATCCGTC-3,
hEpo was incubated with hEpo-transferred rat serum or primer 2 (sense) was 5-GCTAGCAGTAATACTAA
control rat serum, and the samples were then examined CGG-3. The predominant cDNA amplification product
by Western blot analysis by the method described earlier. was predicted to be 688 bp in length.
The anti-hEpo antibody was considered to be present For the detection of hEpo RNA, to digest pGene/V5-
when the signal for hEpo was significantly lower in the hEpo DNA, the RNA solution was incubated with 1 U/mL
cell lysate incubated with hEpo-transferred rat serum RNase-free DNase (Pharmacia Fine Chemicals, Uppsala,
than in that incubated with control rat serum. Sweden) at 37C for 30 minutes. The samples were heated
to 95C for five minutes to inactivate the DNase. Reverse
PCR and RT-PCR analysis transcription (RT) components produced using avian
myeloblastoma virus reverse transcriptase were addedDNA and RNA were isolated from LLC-PK1 cells or
rats hind-limb muscles using Triozol (Gibco). Polymerase to the reaction tubes as described previously [20]. The
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reaction tubes were incubated at 42C for 60 minutes. kin-Elmer Cetus), because Taq DNA polymerase has
terminal transferase activity. The PCR product has ade-The sequence of hEpo primer 1 (antisense) was 5-AGC
CAGGCAGGACATTCGTA-3, and that of primer 2 nine in its 3end. We ligated PCR products and pGEM-
3Zf(), and then sequenced using the dideoxynucleotide(sense) was 5-AACTCTTCCGAGTCTACTCC-3. The
predominant cDNA amplification product was predicted chain-termination reaction of Sanger, Nicklen and Coul-
son [23].to be 511 bp in length (Gene Bank #NM017001). RT
and PCR of glyceraldehyde-3-phosphate dehydrogenase
Isolation of muscle tissue and histological examination(GAPDH) served as a positive control. The primers were
Rats were anesthetized with pentobarbital at indicateddefined by the following cDNA base sequences [21]:
times after in vivo electroporation. The hind-limb mus-primer 1 (antisense) was 5-AGATCCACAACGGAT
cles were quickly excised, fixed in formalin overnight,ACATT-3; primer 2 (sense) was 5-TCCCTCAAGAT
and then dehydrated and paraffin embedded. Thin sec-TGTCAGCAA-3. The cDNA amplification product was
tions were examined with periodic acid-Schiff (PAS)predicted to be 309 bp in length. When GAPDH was used
staining as described previously [24]. Immunohistochem-as an internal control primer, after reverse transcription,
ical staining was performed by a streptavidin and biotin20 L samples were divided into 15 L for each plasmid
technique using hEpo-specific antibody (Santa Cruz), asor hEpo mRNA and a 5 L sample for GAPDH. After
described previously [19]·adjusting the volumes of the sample to 20 L with sterile
water, parallel PCR reactions were run with each set of
Statisticsprimers. To examine the effectiveness of DNAse treat-
The results were given as means  SEM. The differ-ment in degrading residual plasmid DNA, PCR amplifi-
ences were tested using two way-analysis of variancecation of plasmid DNA was performed using primers to
(ANOVA) followed by the Scheffe test for multiple com-a non-transcribed region of the plasmid. The primers
parisons. Two groups were compared by the unpairedhad the following cDNA base sequences: primer 1 (anti-
t test. P 	 0.05 was considered significant.sense), 5-GGTGCATTGGAACGCGCATT-3; primer
2 (sense), 5-TGGCTGGCAACTAGAAGGCA-3. The
predominant cDNA amplification product was predicted RESULTS
to be 598 bp in length.
Expression and regulation of hEpo in LLC-PK1 cellsTo carry out the PCR, 80 L of a PCR reaction buffer
We first examined the regulation of hEpo gene expres-was added to each tube directly. Fifty picomoles of each
sion by MFP in LLC-PK1 cells (Fig. 2). LLC-PK1 cellsof primers 1 and 2 were used per reaction. Deoxynucleo-
were transfected with plasmid DNAs (15 g of pGene/tides were added to a final concentration of 0.20 mmol/L
V5-hEpo and 15 g of pSwitch) by electroporation.each. The reaction buffer (10) was diluted (1/10) to a
When MFP 10 nmol/L was included in the medium, Epofinal composition of: 10 mmol/L Tris-HCl, pH 8.3, 50
secretion into the medium was shown to have increasedmmol/L KCl, 1.5 mmol/L MgCl2 and 0.001% (wt/vol)
from 0 to 35.5 (U/106 cells) at three days. The cell countsgelatin, 2.5 U of Taq DNA polymerase. The tubes were
were more prominently increased in MFP-treated groupplaced in the Programmed Tempcontrol System pro-
(1.5  107 cells/dish) than in the MFP() group (4.5 grammed as follows: (1) incubation at 94C for three
106 cells/dish). Next, the cells were divided into two ex-minutes (initial melt); (2) 30 cycles of the following se-
perimental groups (N 
 5, each group), one culturedquential steps: 94C for one minute (melt), 60C for one
with MFP and the other cultured without MFP. Theminute (anneal), and 72C for three minutes (extend);
Epo secretion of the MFP group continued to increase,and (3) incubation at 72C for seven minutes (final exten-
reaching 45.4 U/106 cells at 9 days (Fig. 2A). On thesion). The treated samples were kept at 4C until the
other hand, the Epo secretion of the MFP-free grouptime of analysis.
showed a decrease to 3.0 U/106 cells at nine days. After
PCR product analysis obtaining this result, we added MFP to the MFP-free
group, and showed an Epo value of 28.6 U/106 cells atThe PCR products were size-fractionated by 2% aga-
12 days (Fig. 2A).rose gel electrophoresis. After electrophoresis and ethid-
We further performed an immunoblot analysis of hu-ium bromide staining, DNA bands were visualized with
man Epo using anti-hEpo antibody (Fig. 2B). No positivean ultraviolet transilluminator (Funakoshi, Tokyo, Japan).
signals were detected in either the control plasmid (con-To confirm that the PCR products were really pGene/
trol plasmid, pGene/V5 and pSwitch with MFP) or theV5-hEpo, pSwitch, and hEpo cDNA, the PCR products
hEpo-plasmid (pGene/V5-Epo) plus pSwitch withoutwere sequenced. PCR products were subcloned into
MFP. However, a clear hEpo signal was detected in thepGEM-3Zf() vector (Promega, Biotec, Madison, WI,
cell lysate of the pGene/V5-Epo plus pSwitch with MFP.USA) as described by Finney [22]. After cutting the
These results demonstrate that MFP regulates the hEpopGEM-3Zf() vector at the Sam I site, thymine was
attached at the 3 end using Taq DNA polymerase (Per- expression by the GeneSwitch system, at least in vitro.
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Fig. 2. Expression and regulation of hEpo in LLC-PK1 cells. (A ) LLC-PK1 cells were transfected with plasmid DNAs (15 g of pGene/V5-hEpo
and 15 g of pSwitch) by electroporation. When mifepristone (MFP; 10 nmol/L) was included in the medium, Epo secretion into the medium was
increased at 3 days. We then divided the cells into two experimental groups: one group cultured with MFP () and one without MFP () (N 

4, each group). At day 9, MFP was added to the both cultures groups. Data are shown as means  SEM. *P 	 0.05 comparisons between the
MFP() and MFP() groups. (B ) Immunoblot analysis of hEpo from cell lysate using anti-hEpo antibody. No positive signals were detected in
either the control plasmid group (control plasmid, pGene/V5 plus pSwitch with MFP, left lane) or pGene/V5-Epo plus pSwitch without MFP
(middle lane). A clear hEpo signal was detected in the cell lysate of the pGene/V5-Epo plus pSwitch with MFP (right lane).
RT-PCR detection of hEpo mRNA and PCR in muscles injected with pGene/V5 (control plasmid)
detection of pGene/V5-hEpo and pSwitch plasmids in plus pSwitch plasmids with MFP; in muscles injected
rat thigh muscle in vivo with pGene/V5-hEpo plus pSwitch plasmids without
MFP; and in muscles injected with pGene/V5-hEpo plusRats (N 
 3 at each of seven time points, for a total of
pSwitch plasmids with MFP. Positive hEpo protein and21 rats) were injected intramuscularly with the following
mRNA were detected only in the third group (Fig. 3C).plasmid DNAs: 100 g of pGene/V5-hEpo plus 100 g
To compare the efficiency of Epo mRNA and proteinof pSwitch. Electroporation was performed immediately
expression with or without electroporation, we examinedafter plasmid injection. MFP was injected every three
the protein expression and presence of hEpo mRNA indays up to 50 days. The muscles injected with pGene/
the thigh muscle 10 days after injection in two differentV5-hEpo plus pSwitch plasmids were resected at indi-
experimental conditions: in muscles injected with pGene/cated times after injection. The positive PCR signals of
V5-hEpo plus pSwitch plasmids with electroporation andpGene/V5-hEpo plus pSwitch plasmids were detected
MFP; and in muscles injected with pGene/V5-hEpo plusup to 50 days after the plasmid injection into the thigh
pSwitch plasmids with MFP but without electroporation.muscle. RT-PCR was used to determine the presence of
The control group received neither the plasmid injectionhEpo mRNA. The positive signal of hEpo mRNA also
nor electroporation. Strong positive hEpo protein andwas detected up to 50 days after the plasmid injection
mRNA were detected in the group treated with electro-in the presence of MFP administration (Fig. 3A). The
poration and MFP (Fig. 3D). In the group treated withcontrol lane of Figure 3A is PCR amplification of DNA
MFP but without electroporation, a weak positive bandand RNA from an uninjected muscle specimen. To exam-
was detected by RT-PCR, however, none was detectedine the effectiveness of DNAse treatment in degrading
by immunoblot analysis (Fig. 3D).residual plasmid DNA, PCR amplification of plasmid
DNA was performed using primers to a non-transcribed
Changes of hematocrit and serum humanregion of the plasmid. As shown in Figure 3B, hEpo
erythropoietin levels in ratsplasmid DNA was not detected with DNAse treatment.
Rats (N 
 24) were injected intramuscularly with theWe examined the protein expression and presence of
100 g of pGene/V5-hEpo and 100 g of pSwitch, andmRNA of hEpo in the thigh muscle 10 days after injec-
tion in three different experimental conditions; that is, then were divided into three groups: one group adminis-
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Fig. 3. Reverse transcription-polymerase chain reaction (RT-PCR) detection and immunoblot analysis of hEpo expression and PCR detection
of pGene/V5-hEpo and pSwitch plasmids in rat thigh muscle in vivo. (A ) Rats were injected intramuscularly with the following plasmid DNAs:
100 g of pGene/V5-hEpo and 100 g of pSwitch. MFP was injected every 3 days up to 30 days. DNA and total RNA were extracted from injected
muscle at the indicated times. PCR analyses were performed for pGene/V5-hEpo and pSwitch plasmids, while RT-PCR analyses were performed
for Epo mRNA and GAPDH mRNA (positive control). The control lane is PCR amplification of DNA and RNA from an uninjected muscle
specimen. (B ) The efficacy of DNAse treatment in degrading residual plasmid DNA was examined. We performed PCR amplification of plasmid
DNA using primers to non-transcribed regions of the plasmid. Human Epo plasmid DNA was not detected with DNAse treatment. (C ) Immunoblot
and RT-PCR analyses for hEpo expression were performed from injected muscle at 10 days after injection. We examined three different experimental
conditions (N 
 3, in each experiments): in muscle injected with pGene/V5 (control plasmid) plus pSwitch plasmids and MFP; in muscle injected
with pGene/V5-hEpo plus pSwitch plasmids without MFP; and in muscle injected with pGene/V5-hEpo plus pSwitch plasmids with MFP. (D )
Effects of electroporation on Epo mRNA and protein expression in rat muscle. The protein expression and presence of hEpo mRNA were
examined in the thigh muscle at 10 days after injection under two different experimental conditions: in muscle injected with pGene/V5-hEpo plus
pSwitch plasmids with electroporation and MFP; and in muscles injected with pGene/V5-hEpo plus pSwitch plasmids with MFP but without
electroporation. The control received neither plasmid injection nor electroporation. (N 
 3, in each group)
tered MFP for 50 days; a second group administered pGene/V5-hEpo group), 70 mg/kg MFP was injected
intraperitoneally every three days. In the first groupMFP for the first 15 days and re-challenged from days
30 to day 50 days; and a third group not administered [pGene/V5-hEpo and MFP() for 50 days] the hemato-
crit levels increased continuously, rising from 41.2% be-MFP. A fourth group of rats (N 
 6) was injected intra-
muscularly with 100 g of pGene/V5 (control plasmid) fore the injection to 52.7% on day 15, to 54.9% on day
25, to 55.0% on day 30, to 54.0% on day 40, and toand 100 g of pSwitch. Electroporation was performed
immediately after plasmid injection. In the MFP-treated 53.8% on day 50 (Fig. 4). In the second group [pGene/
V5-hEpo and MFP() for 15 days, and re-challengedrats (N 
 6 of the pGene/V5 group, N 
 12 of the
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Fig. 5. Increase in the serum human Epo level in rats injected with
pGene/V5-hEpo and pSwitch plasmid with MFP treatment. Rats (N 
Fig. 4. Increase in hematocrit in rats injected with pGene/V5-hEpo
18) were injected intramuscularly with 100 g of pGene/V5-hEpo andplus pSwitch plasmid with MFP treatment. Rats (N 
 18) were injected
100g of pSwitch, and then divided into three groups: one group adminis-intramuscularly with 100 g of pGene/V5-hEpo and 100 g of pSwitch,
tered MFP for 50 days (); a second group administered MFP for theand then divided into three groups: one group administered MFP for
first 15 days and then re-administered from day 30 to day 50 (); and50 days (); a second group administered MFP for the first 15 days
a third group not administered MFP (). Another group (fourth group,and then re-administered MFP from day 30 to day 50 (); and a third
) of rats (N
 6) was injected intramuscularly with 100g of pGene/V5group not administered MFP (). A fourth group, () of rats (N 
 6)
plus 100 g of pSwitch and treated with MFP. In the MFP-treated ratswas injected intramuscularly with 100 g of pGene/V5 plus 100 g of
(N 
 6 of the pGene/V5 group, N 
 12 of the pGene/V5-hEpo group),pSwitch and treated with MFP. In the MFP-treated rats (N 
 6 of the
70 mg/kg of MFP was injected intraperitoneally every 3 days. Data arepGene/V5 group, N 
 12 of the pGene/V5-hEpo group), 70 mg/kg
shown as means  SEM. *P 	 0.05 comparisons with the control ratsMFP was injected intraperitoneally every 3 days. Data are shown as
(fourth group injected with pGene/V5 plus pSwitch).means  SEM. *P 	 0.05 comparisons with the control rats (fourth
group injected with pGene/V5 plus pSwitch).
In the second group (in which MFP was stopped at 15
days, and re-challenged from 30 to 50 days), the serumfrom 30 to 50 days] the hematocrit levels fluctuated,
hEpo levels fluctuated after day 15, falling to 23.5rising steadily from 42.7% before the injection to 52.5%
mU/mL on day 30, rising again to 54.3 mU/mL on dayon day 15, then falling to 47.1% on day 20 and 43.9% on
40, and 59.2 mU/mL on day 50. There was no significantday 30, then rising to 46.5% on day 40 and to 50.0% on
change in the hEpo level in the pGene/V5-hEpo andday 50 (Fig. 4). In the third [pGene/V5-hEpo and MFP()]
MFP() group or pGene/V5 and MFP() group. Usingand fourth [pGene/V5 and MFP()] groups, the hemato-
absorbance experiments, we detected anti-hEpo anti-crit levels did not change significantly (Fig. 4). In further
body from the serum of four rats in the pGene/V5-hEpotests to determine how hematocrit levels responded to
and MFP() group at 50 days (data not shown). Wethe injection of MFP alone (MFP injection every 3 days for
also examined how the hEpo levels responded to the50 days with no plasmid injection), no significant changes
injection of MFP alone (MFP injection every 3 days forin the hematocrit levels were found (data not shown).
50 days with no plasmid injection). In these MFP-treatedThe serum hEpo levels increased from the preinjection
rats, the hEpo levels did not significantly change (datalevel of 11.0 to 82.3 and 79.8 mU/mL on day 10 in the
not shown).first group [pGene/V5-hEpo and MFP() for 50 days]
and second group [pGene/V5-hEpo & MFP() for 15
Expression of hEpo in rat thigh muscle in vivodays, and re-challenged from 35 to 50 days], respectively
(Fig. 5). In the first group, the serum hEpo level contin- An immunohistological examination also was per-
formed using anti-human Epo antibody in the thigh mus-ued to gradually increase from day 10, up to a peak of
123.6 mU/mL on day 20, and then it fell back slightly to cle of the pGene/V5-hEpo and MFP() group. Human
Epo expression was detected in the thigh muscle of the117.1 mU/mL on day 30, and 110.2 mU/mL on day 50.
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Fig. 6. In vivo human Epo expression in rat thigh muscle. (A ) Immunohistological examination using anti-human Epo antibody in the thigh
muscle injected with pGene/V5-hEpo, pSwitch and MFP() group rats at day 14 (400). Brown staining (arrowheads) indicates hEpo expression
in muscle fiber. (B ) Immunohistological examination using anti-human Epo antibody in the thigh muscle of the control (no treatment) rats. (C )
PAS staining of the thigh muscle of the pGene/V5-hEpo, pSwitch & MFP() group rats at day 14 (400). Cell infiltration was observed around
the area where transgene was expressed. (D ) PAS staining of the thigh muscle of the pGene/V5-hEpo, electroporation() and MFP() treated
rats. Slight neutrophil infiltration is observed in the muscle. (E ) PAS staining of the thigh muscle of the pGene/V5-hEpo, electroporation() and
MFP() treated rats. (F ) PAS staining of the thigh muscle of the pGene/V5-hEpo, electroporation() and MFP() treated rats. (G ) PAS staining
of the thigh muscle of the plasmid() and electroporation() treated rats. No remarkable neutrophil infiltration is observed in panels E-G.
pGene/V5-hEpo and MFP() treated rats on day 14 neutrophil infiltration was due to transgene expression
rather than electroporation.(Fig. 6A). In contrast, no such signal was detected in the
control (no treatment, no plasmid, no electroporation)
In vivo electroporation dramatically increased therats (Fig. 6B), pGene/V5-hEpo and MFP() treated rats,
hematocrit level and hEpo levelor pGene/V5 and MFP() treated rats on day 14 (data
not shown). In the rat skeletal muscle of the pGene/ Next, the hematocrit levels were compared in rats
V5-hEpo, electroporation() and MFP() treated rats, injected with different DNA doses (10, 50, and 100 g)
of pGene/V5-hEpo plus pSwitch and MFP () with orneutrophil and fibroblast infiltration was observed around
the area of transgene expression at day 14, as shown in without in vivo electroporation on day 25. The hemato-
crit level increased in proportion to the dose of DNA,Figure 6C. There was only slight neutrophil infiltration
in the pGene/V5-hEpo, electroporation() and MFP() as shown in Figure 7. The increases in hematocrit levels
were significantly higher in the rats treated by in vivotreated rats (Fig. 6D), the group that expressed low
amounts of hEpo (Figs. 3C and 7). There was no remark- electroporation than in the rats that received no electro-
poration (at doses of 50 g and 100 g). The increasesable neutrophil infiltration in the pGene/V5-hEpo, elec-
troporation () and MFP() treated rats (Fig. 6E), in hEpo levels were significantly higher in the rats treated
by in vivo electroporation (120.1 mU/mL) than in thethe pGene/V5-hEpo, electroporation () and MFP()
treated rats (Fig. 6F), or plasmid() and electroporation rats that received no electroporation (18.1 mU/mL) at
doses of 100 g of plasmid on day 25.() treated rats (Fig. 6G). These data indicated that the
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periments using a mixture of two adeno-associated virus
vectors, one expressing the transcription factor chimeras
and one containing Epo under the control of a promoter
responsive to the transcription factor. After injecting this
system into the skeletal muscle of immunocompetent
mice and rhesus monkeys, serum Epo was successfully
elevated under the control of rapamycin for up to 150
days [12]. While these adeno-associated virus systems
have proven very useful for gene delivery, the methods
require relatively large amount of adeno-associated virus,
as well as intensive labor to purify the virus. Rivera et al
reported a similar rapamycin-regulatable growth hormone
gene therapy [13]. In their report using immunodeficient
mice, long-term regulated expression of growth hormone
was achieved within the use of separate adenovirus andFig. 7. Comparison of hematocrit levels in rats injected different DNA
doses with or without in vivo electroporation (EP). The hematocrit adeno-associated virus vectors, one encoding an induc-
levels in rat injected with different DNA doses (10, 50, and 100 g) of ible human growth hormone target gene, and the otherpGene/V5-hEpo plus pSwitch with MFP() with or without in vivo
encoding a bipartite rapamycin-regulated transcriptionelectroporation at day 25 are shown. The data are mean  SEM in 5
animals. *Significantly different from saline control (P 	 0.05); #signifi- factor. In immunocompetent mice, the expression of the
cantly different between EP() and EP() of same DNA doses (P 	 adenovirus-directed growth hormone was quickly extin-0.05).
guished. Several reports demonstrated that adenovirus
vector elicited an efficient expression of Epo in immuno-
deficient mice [14]. Thus, the utilization of adenovirus for
DISCUSSION therapeutic purposes is limited by the transient nature of
the transgene expression and systemic toxicity, both ofThis study demonstrates that ligand-dependent regu-
lation of hEpo expression can be achieved after the deliv- which are due to the inflammatory and immune responses
triggered by the residual expression of viral proteinsery of a two-plasmid GeneSwitch system to the hind-
limb muscles of rats. Our results also demonstrate that [15, 31]. The development of adenovirus vectors with all
viral coding sequences deleted offers the prospect of ain vivo electroporation dramatically increases the effi-
ciency of the gene expression. safer and more efficient way to deliver genes [13, 32]. This
improved helper-dependent adenoviral vector allowedTreatment of patients with end-stage renal failure by
recombinant hEpo has proven effective in correcting persistent gene expression after intramuscular delivery
and overcame preexisting immunity to adenovirus [15].anemia, but it incurs substantial costs. An alternative
method to deliver Epo continuously is by gene therapy, Ex vivo gene transfer also has been investigated for
Epo gene transfer. Bohl, Naffakh and Heard reportedeither by introducing the Epo gene into autologous cells
ex vivo [9, 10, 25] and transferring the modified cells that retrovirus-engineered myoblast expressing rtTA
(coding sequences for the tetracycline reverse transacti-back into the individual, or by directly transferring the
Epo gene in vivo using an adenovirus vector, adeno- vator), the chimeric transactivator conferring doxy-
cyclin-inducible gene expression, can be stably engraftedassociated vector, or naked plasmid [6, 12, 26–31].
However, ex vivo gene transfer is both labor intensive in mice, thus allowing long-term control of Epo secretion
in vivo [33]. It is less expensive and easy to perform.and expensive because it requires the isolation, growth,
and transduction of primary human myoblasts from each Currently available vectors for the in vivo transfer of the
Epo gene into muscle include plasmid DNA, replication-patient. Several novel methods have proven successful in
attaining long-term regulated expression of therapeutic defective adenovirus vectors, and adeno-associated virus
vectors. A large quantity of highly purified plasmid DNAhormones such as growth hormone and Epo. In subjects
treated by intramuscular injection of adeno-associated is easily and inexpensively obtained, and gene transfer
can be repeated without apparent immune response tovector, tetracycline was found to adequately control Epo
production [11]. Bohl et al reported that a single intra- the DNA vector. However, plasmid vectors are ineffi-
ciently taken up by muscle cells and manifest relativelymuscular injection of an adeno-associated virus vector
containing the components of the tetracycline-inducible low-level expression compared with viral vectors [34, 35].
Indeed, there are only a few reports on the use of plasmidregulatable system and a mouse Epo cDNA resulted in
elevation of hematocrit and serum Epo concentration vectors for the in vivo transfer of the Epo gene [36].
Gene transfer by in vivo electroporation has beenfor up to 30-weeks in immunocompetent mice [11]. Other
groups recently demonstrated a rapamycin-regulatable shown to be effective for introducing DNA into mouse
skin [37], chicken embryos [38], rat liver [39], mousegene expression system [12, 13]. Ye et al conducted ex-
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melanoma [40], rat brain [41], and rat corneal endothe- system and in vivo electroporation is a useful procedure
for efficient drug-regulated delivery of Epo.lium [42]. Moreover, it was demonstrated that gene trans-
fer into mouse muscles by this approach is much more
effective than that by simple intramuscular DNA injec- ACKNOWLEDGMENTS
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